Direct Identification of Enteroviruses in Cerebrospinal Fluid of Patients with Suspected Meningitis by Nested PCR Amplification

Alexandr Krasota, Natalia Loginovskih, Olga Ivanova and Galina Lipskaya

Abstract: Enteroviruses, the most common human viral pathogens worldwide, have been associated with serous meningitis, encephalitis, syndrome of acute flaccid paralysis, myocarditis and the onset of diabetes type 1. In the future, the rapid identification of the etiological agent would allow to adjust the therapy promptly and thereby improve the course of the disease and prognosis. We developed RT-nested PCR amplification of the genomic region coding viral structural protein VP1 for direct identification of enteroviruses in clinical specimens and compared it with the existing analogs. One-hundred-fifty-nine cerebrospinal fluids (CSF) from patients with suspected meningitis were studied. The amplification of VP1 genomic region using the new method was achieved for 86 (54.1%) patients compared with 75 (47.2%), 53 (33.3%) and 31 (19.5%) achieved with previously published methods. We identified 11 serotypes of the Enterovirus species B in 2012, including relatively rare echovirus 14 (E-14), E-15 and E-32, and eight serotypes of species B and 5 enteroviruses A71 (EV-A71) in 2013. The developed method can be useful for direct identification of enteroviruses in clinical material with the low virus loads such as CSF.

Keywords: Enterovirus; nested PCR; cerebrospinal fluids (CSF); direct genotyping; detection; identification; sequencing

1. Introduction

The Enterovirus (EV) genus of the Picornaviridae family is divided into twelve species. Four human enterovirus species A, B, C, D comprises more than 100 serotypes. The EV genome, ribonucleic acid of positive polarity (+RNA), consists of approximately 7100–7500 base pairs. The virus-encoded RNA-dependent RNA polymerase does not possess proofreading property thereby endowing high mutation rate during replication [1]. In addition, Picornavirus genomes are subjected to frequent recombination events [2–8], adding to their plasticity and allowing rapid adaptation to therapeutic and/or immune pressure. EVs are the most common human viral pathogens [9] causing a broad range of illnesses including serous meningitis [10], encephalitis [10,11], syndrome of acute flaccid paralysis [12], myocarditis [13,14] and the onset of diabetes type 1 [15]. The EV infections of central nervous system (CNS) were associated with an increased risk of adult onset of schizophrenia or other psychosis [16]. In some cases, the CNS pathologies have detrimental impact on other organs as it was shown for fatal cases of cardiomyopathies caused by EV-A71 affected CNS [17].

With severe injuries of the CNS or heart tissue, the disease has the adverse prognosis; therefore, an accurate diagnosis is important for effective treatment. A routine medical practice of managing...
CNS and myocard viral pathologies with only standard symptomatic therapy is widely accepted, although antiviral and specific therapies could be used for improving the course and outcome of the disease. For the diseases with EV etiology, not only the virus detection but the virus identification and genotyping are important because distinct serotypes and their genogroups can differ in pathogenicity and virulence [18,19]. The efficacy of antiviral drugs in relation of certain serotypes and genogroups differs [20] therefore this information should be considered in the decision of using antiviral and specific therapies in the management of patients in future.

The precise intravital diagnostics of CNS can be established only by the detection of virus in CSF and subsequent virus serotyping. In many cases, the virus loads in such clinical specimens are quite low [21], therefore the amplification of genome region appropriate for serotyping requires highly sensitive PCR technics. The genome region coding enterovirus structural protein VP1 is commonly used for determination of serotype, genogroup and phylogenetic relationship of virus.

The aim of this work was to develop a highly sensitive method for rapid direct identification of enteroviruses by amplification of the whole genome region coding for viral structural protein VP1 and to compare it with the existing analogs.

The direct EV serotyping from CSF of patients with suspected meningitis was performed with different methods developed for direct investigation of clinical material, including nested PCR we have developed for amplification of the whole VP1 sequence.

The existing seminested PCRs for amplification the whole VP1 genomic region [22] or its part [23] and nested PCR for amplification of the part of VP1 [24] were used in this investigation for comparison.

2. Materials and Methods

2.1. Patients

CSF samples were collected from patients with suspected aseptic meningitis admitted to the hospitals in Omskaya oblast (West Siberia, Russia), within the framework of the national Public Health program “Non-polio Enterovirus Infection Surveillance and Prevention”. Collected specimens were delivered to Omsk virological laboratory and stored at −80 °C. The diagnosis of the suspected viral aseptic meningitis was based on clinical symptoms such as headache, fever, rigidity of neck, nausea/vomiting, photophobia, and negative CSF culture for bacterial test. Eighty-eight patients were admitted in 2012 and 71 in 2013. The retrospective direct serotyping of CSF samples was performed in Moscow in World Health Organisation Polio Regional Reference Laboratory for Russian Federation and several New Independent States.

2.2. General Characteristic of Patients Included in the Study

In 2012, 88 patients were admitted (7 adults, mean age 23.6 years and 81 children, mean age 8.1 years). The male/female ratio was 1.3:1 and 1.4:1 in adults and children, respectively. The age range was from 18 to 32 years in adults and from 2 to 14 years in children. In 2013, 71 patients were admitted (9 adults, mean age 23.1 years and 62 children, mean age 6.5 years). The male/female ratio was 1.4:1 and 1.5:1 in adults and children, respectively. The age range was from 17 to 29 years in adults and from 1 to 14 years in children. The CSF samples were collected during the whole years.

2.3. RNA Extraction

DNase (1 µL) and 1 µL RNase A (Thermo Scientific EU, Vilnius, Lithuania) were added to 100 µL of each CSF sample and incubated at 37 °C for 30 min. For RNA extraction RNeasy® Mini Kit (Qiagen, Hilden, Germany) was used according to the manufactures instructions. The RNA was eluted in 30 µL of H2O.

2.4. Reverse Transcription (RT)

Synthesis of complementary deoxyribonucleic acid (cDNA) was carried out in 20 µL reaction mixture containing 4 µL of 5× Super Script III First-Strand Buffer (Invitrogen, Carlsbad, CA, USA)
4 µL of 25 M hexamer primers, 2 µL of 0.1 M DTT, 0.5 µL of 20 mM nucleotide mixture, 100 U of Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA), 20 U of RiboLock RNase Inhibitor (Thermo Scientific EU, Vilnius, Lithuania) and 8.5 µL of the extracted RNA with 25 °C for 5 min, 50 °C for 60 min, and 95 °C for 5 min.

2.5. Nested PCR

In the first-round PCR (total volume 50 µL), 5 µL of RT mixture was used (PCR 1) consisting of 24 µL of H2O, 5 µL of 10× Dream Taq PCR buffer (Thermo Scientific EU, Vilnius, Lithuania), 5 µL of each 10 µM 131 and 224 primers [25], (Table 1), 5 µL of 2 mM nucleotide mixture and 1 µL (5 U) of Dream Taq DNA polymerase (Thermo Scientific EU, Vilnius, Lithuania) using the following conditions: 95 °C for 5 min for denaturation, then 40 cycles of 30 s at 95 °C, 45 s at 42 °C, ramp 40%, and 1 min 50 s at 60 °C.

Table 1. Oligonucleotide primers used in this study and the resulted amplicons.

| Primer     | Position, nt | Resulted Amplicon, nt |
|------------|--------------|-----------------------|
| 224 d      | 1977–1996 a  | 1856                  |
| 131 d      | 3832–3812 a  |                       |
| HEVBS1695 e| 2375–2409 b  | 1093                  |
| HEVBR132 e | 3467–3432 b  |                       |
| AK1 c      | 2298–2320 c  | 1373                  |
| AK3 c      | 3670–3645 c  |                       |

| a The positions are given relative to the genome of poliovirus 1, strain Mahoney; | b The positions are given relative to the genome of echovirus 30, strain Bastiani; | c The positions are given relative to the genome of enterovirus A71, strain BJ303; | d Primers were described in [25]; | e Primers were described in [22]. |

The second-round nested PCR (PCR 2) contained 2 µL of the first-round PCR, 27 µL of H2O, 5 µL of 10× Dream Taq PCR buffer (Thermo Scientific EU, Vilnius, Lithuania), 5 µL of each 10 µM HEVBS1695 and HEVBR132 primers [22] or 5 µL of each 10 µM primers for EV-A71 AK1: 5′−ATATGGTATCAGACNAAYTAYGT-3′ and AK3: 5′−AGGATACCACCGCARTCNCCNGGYTC-3′, 5 µL of 2 mM nucleotide mixture and 1 µL (5 U) of Dream Taq DNA polymerase (Thermo Scientific EU, Vilnius, Lithuania). PCR 2 was carried out under the following conditions: 95 °C for 2 min and then 40 cycles of 15 s at 95 °C, 30 s at 55 °C, 1 min 30 s at 68 °C and finally postcycling stage 10 min at 68 °C.

Standard precautions were undertaken to avoid the risks of contamination. RNase free water as a negative control and E-9 RNA, cDNA and PCR1 product were used as positive controls for RT, PCR 1 and PCR 2 respectively. As additional methods, we used two seminested PCRs according to [22,23] and 1 nested PCR according to [24]. All amplifications were performed on Applied BiosystemsVerity amplificator (Singapore). PCR products were separated and visualized on 1.5% agarose gel stained with ethidium bromide and were purified using QIA quick® gel extraction kit (Qiagen, Hilden, Germany) according to manufacturers instructions.

2.6. Sequencing and Sequences Analysis

Sequencing was performed on ABI Prism 3130 genetic analyzer using Big Dye Terminator sequencing kit v. 3.1 (Applied Biosystems, Forester city, CA, USA). DNA Star TagMan program (DNA STAR, Madison, WI, USA) was used for analyzing raw sequence data. To determine the EV genotype, we compared the sequence homology between the amplified PCR products and sequences available in GenBank. The obtained sequences were assigned as the serotypes which gave the highest identity score in BLAST program [26].
2.7. Assay Sensitivity

The sensitivity relative to the results of cell culture infectivity of E-6 enterovirus serotype strain 52,725 was determined. The RNA was extracted from 100 µL of tenfold virus dilutions from $10^5$ to $10^{-2}$ cell culture infectious dose 50% end-point units (CCID$_{50}$) in negative CSFs with RNeasy® Mini Kit (Qiagen, USA) according to the manufactures instructions. RNAs representing from $10^4$ to $10^{-3}$ CCID$_{50}$ per 5 µL were tested with VP1 RT-nested PCR amplification. Super Script III reverse transcriptase was used in RT reaction according to manufactures instructions.

The sequences of EVs identified in our assay were deposited in GeneBank sequence database, accession nos KU133569–KU133654.

3. Results

3.1. Comparative Analysis of the Existing and New Amplification Methods

One-hundred-fifty-nine CSF samples from patients with suspected serous meningitis were studied for enteroviruses. We evaluated one nested PCR and two seminested PCRs previously described in the literature that amplified full or a part of the genomic region coding for the viral structural protein VP1 [22–24]. Nested PCR amplification according to Casas I. et al. [24] resulted in the appearance of non-specific bands in gels and the PCR product of expected molecular weight was generated in 31 samples (19.5%). Seminested PCR according to Nix W.A. et al. [23], except the using of FastStart Taq DNA polymerase in the second round of PCR, detected EVs in 75 (47.2%) of CSF samples. The seminested PCR have been developed for amplification of the whole VP1 sequence for enteroviruses species B [22]. Using this method, we obtained the PCR product of correct molecular weight (Figure 1A) from 53 (33.3%) CSF samples.

![Figure 1](image_url)

**Figure 1.** Gel electrophoresis of amplified CSF samples according to [22] above (A) and according to our method ant the bottom; (B) M-molecular weight marker. Black arrows indicate the bands which correspond to calculated weight of the amplicons.

Seminested PCR according to [23] was highly sensitive but amplified only ~350 to 400 of the VP1 genomic region and seminested PCR according to [22] missed 22 positive samples. Nested PCR [24] designed to amplify the part of the VP1 sequence showed low sensitivity compared with other tested methods.

As we needed a highly sensitive method to amplify the whole VP1 region and none of the tested methods was appropriate for our purpose, the new nested PCR allowing this was developed. In order to reach maximum sensitivity and specificity, we used highly degenerate primers 224 and 131 [25] with highly degenerate conditions for the first round of PCR and CODEHOP (Consensus-Degenerate
Hybrid Oligonucleotide Primer) nested primers HEVBS1694-HEVBR132 and AK1-AK3 with adjusted conditions for the second round. The CODEHOP technology is a powerful tool for primer design which ensures high sensitivity and at the same time high specificity of amplification. They consist of 5′ consensus and 3′ degenerate parts and this approach provides increased sensitivity and the ability to amplify different serotypes/variants of the virus [27]. The primers HEVBS1694-HEVBR132 and AK1-AK3 amplify the whole VP1 genome region. Using this nested PCR, we identified EVs from 86 CSF samples (54.1%) including almost all samples that were positive in other methods. Also the amount of PCR products of the predicted molecular weight increased significantly compared with method [22] which also allowed obtaining of the full VP1 sequence (Figure 1B). The inner primers AK1 and AK3 were used to amplify VP1 genome region of EV-A71. These primers were designed to conservative sequences of VP3 and 2A genome regions of EV-A71 with the use of CODEHOP technology. AK1, AK3 primers allow to obtain PCR products of CV-B5 and E-18 and the resulting amplicon is longer than the PCR product of HEVBS1659 and HEVBR132 primers thereby we compared sequences flanked with AK1-AK3 primers with the database of GeneBank.

3.2. Assay Sensitivity

The VP1 RT nested PCR assay detected RNA extracted from $10^{-2}$ CCID$_{50}$ per 5 µL of E-6 virus indicating that the assay is at least 100 fold more sensitive than cell culture for this strain of virus since 1 CCID$_{50}$ defines the cell culture end point.

3.3. Retrospective Direct Genotyping of Enteroviruses Detected in CSF of Patients Hospitalized in 2012

Eighty-eight patients with suspected meningitis were admitted to the hospitals in Omskaya oblast in 2012 and were subjected to lumbal puncture. RNAs extracted from CSFs were amplified with our new nested PCR method and the amplicons of predicted molecular weight were obtained for 47 (53.4%) samples. Successful serotyping was achieved for all 47 positive samples. The serotype was assigned to each sample as the type which gave the maximal score by the means of BLAST program according to the comparison of obtained sequence with all sequences in the database of GeneBank. 11 serotypes of species B were identified in CSFs in 2012 including relatively rare E-14, E-15 and E-32 (Table 2).

Table 2. Direct serotyping of enteroviruses detected in cerebrospinal fluids (CSFs) of patients with serous meningitis admitted in 2012 and 2013.

| No. | CSF Specimen | EV Serotype | Accession No. | No. | CSF Specimen | EV Serotype | Accession No. |
|-----|--------------|-------------|---------------|-----|--------------|-------------|---------------|
| 1   | 257-CSF/RUS/Omsk/2012 | E-6 | KU133571 | 1   | 376-CSF/RUS/Omsk/2013 | E-11 | KU133616 |
| 2   | 259-CSF/RUS/Omsk/2012 | E-6 | KU133573 | 2   | 377-CSF/RUS/Omsk/2013 | E-11 | KU133617 |
| 3   | 266-CSF/RUS/Omsk/2012 | E-6 | KU133577 | 3   | 380-CSF/RUS/Omsk/2013 | E-11 | KU133618 |
| 4   | 268-CSF/RUS/Omsk/2012 | E-6 | KU133579 | 4   | 381-CSF/RUS/Omsk/2013 | E-11 | KU133619 |
| 5   | 271-CSF/RUS/Omsk/2012 | E-6 | KU133581 | 5   | 394-CSF/RUS/Omsk/2013 | E-11 | KU133626 |
| 6   | 272-CSF/RUS/Omsk/2012 | E-6 | KU133582 | 6   | 395-CSF/RUS/Omsk/2013 | E-11 | KU133627 |
| 7   | 274-CSF/RUS/Omsk/2012 | E-6 | KU133583 | 7   | 400-CSF/RUS/Omsk/2013 | E-11 | KU133629 |
| 8   | 320-CSF/RUS/Omsk/2012 | E-6 | KU133602 | 8   | 402-CSF/RUS/Omsk/2013 | E-11 | KU133630 |
| 9   | 321-CSF/RUS/Omsk/2012 | E-6 | KU133603 | 9   | 404-CSF/RUS/Omsk/2013 | E-11 | KU133632 |
| 10  | 322-CSF/RUS/Omsk/2012 | E-6 | KU133604 | 10  | 412-CSF/RUS/Omsk/2013 | E-11 | KU133637 |
| 11  | 324-CSF/RUS/Omsk/2012 | E-6 | KU133605 | 11  | 419-CSF/RUS/Omsk/2013 | E-11 | KU133639 |
| 12  | 329-CSF/RUS/Omsk/2012 | E-6 | KU133608 | 12  | 430-CSF/RUS/Omsk/2013 | E-11 | KU133643 |
| 13  | 332-CSF/RUS/Omsk/2012 | E-6 | KU133610 | 13  | 443-CSF/RUS/Omsk/2013 | E-11 | KU133647 |
| 14  | 338-CSF/RUS/Omsk/2012 | E-6 | KU133612 | 14  | 445-CSF/RUS/Omsk/2013 | E-11 | KU133648 |
| 15  | 340-CSF/RUS/Omsk/2012 | E-6 | KU133613 | 15  | 446-CSF/RUS/Omsk/2013 | E-11 | KU133649 |
| 16  | 341-CSF/RUS/Omsk/2012 | E-6 | KU133614 | 16  | 448-CSF/RUS/Omsk/2013 | E-11 | KU133650 |
| 17  | 261-CSF/RUS/Omsk/2012 | CV-A9 | KU133574 | 17  | 452-CSF/RUS/Omsk/2013 | E-11 | KU133653 |
| 18  | 263-CSF/RUS/Omsk/2012 | CV-A9 | KU133575 | 18  | 391-CSF/RUS/Omsk/2013 | EVA71 | KU133624 |
| 19  | 270-CSF/RUS/Omsk/2012 | CV-A9 | KU133580 | 19  | 434-CSF/RUS/Omsk/2013 | EVA71 | KU133644 |
| 20  | 296-CSF/RUS/Omsk/2012 | CV-A9 | KU133590 | 20  | 437-CSF/RUS/Omsk/2013 | EVA71 | KU133645 |
| 21  | 297-CSF/RUS/Omsk/2012 | CV-A9 | KU133591 | 21  | 450-CSF/RUS/Omsk/2013 | EVA71 | KU133651 |
| 22  | 299-CSF/RUS/Omsk/2012 | CV-A9 | KU133593 | 22  | 451-CSF/RUS/Omsk/2013 | EVA71 | KU133652 |
| 23  | 302-CSF/RUS/Omsk/2012 | CV-A9 | KU133594 | 23  | 382-CSF/RUS/Omsk/2013 | CV-A9 | KU133620 |
| 24  | 309-CSF/RUS/Omsk/2012 | CV-A9 | KU133597 | 24  | 393-CSF/RUS/Omsk/2013 | CV-A9 | KU133625 |
| 25  | 312-CSF/RUS/Omsk/2012 | CV-A9 | KU133599 | 25  | 408-CSF/RUS/Omsk/2013 | CV-A9 | KU133635 |
Table 2. Cont.

| No. | CSF Specimen     | EV Serotype | Accession No. | No. | CSF Specimen     | EV Serotype | Accession No. |
|-----|------------------|-------------|---------------|-----|------------------|-------------|---------------|
| 26  | 313-CSF/RUS/Omsk/2012 | CV-A9       | KU133600      | 26  | 409-CSF/RUS/Omsk/2013 | CV-A9       | KU133636      |
| 27  | 325-CSF/RUS/Omsk/2012 | CV-A9       | KU133606      | 27  | 386-CSF/RUS/Omsk/2013 | E-7         | KU133622      |
| 28  | 256-CSF/RUS/Omsk/2012 | E-9         | KU133570      | 28  | 413-CSF/RUS/Omsk/2013 | E-7         | KU133638      |
| 29  | 267-CSF/RUS/Omsk/2012 | E-9         | KU133578      | 29  | 428-CSF/RUS/Omsk/2013 | E-7         | KU133641      |
| 30  | 287-CSF/RUS/Omsk/2012 | E-9         | KU133589      | 30  | 403-CSF/RUS/Omsk/2013 | E-30        | KU133631      |
| 31  | 307-CSF/RUS/Omsk/2012 | E-9         | KU133596      | 31  | 405-CSF/RUS/Omsk/2013 | E-30        | KU133633      |
| 32  | 342-CSF/RUS/Omsk/2012 | E-9         | KU133615      | 32  | 455-CSF/RUS/Omsk/2013 | E-30        | KU133654      |
| 33  | 258-CSF/RUS/Omsk/2012 | CV-B1       | KU133572      | 33  | 390-CSF/RUS/Omsk/2013 | CV-B2       | KU133623      |
| 34  | 277-CSF/RUS/Omsk/2012 | CV-B1       | KU133584      | 34  | 407-CSF/RUS/Omsk/2013 | CV-B2       | KU133634      |
| 35  | 298-CSF/RUS/Omsk/2012 | CV-B1       | KU133592      | 35  | 425-CSF/RUS/Omsk/2013 | CV-B2       | KU133640      |
| 36  | 265-CSF/RUS/Omsk/2012 | CV-B1       | KU133576      | 36  | 383-CSF/RUS/Omsk/2013 | E-18        | KU133621      |
| 37  | 326-CSF/RUS/Omsk/2012 | CV-B1       | KU133607      | 37  | 399-CSF/RUS/Omsk/2013 | E-18        | KU133628      |
| 38  | 297-CSF/RUS/Omsk/2012 | E-11        | KU133585      | 38  | 429-CSF/RUS/Omsk/2013 | CV-B4       | KU133642      |
| 39  | 282-CSF/RUS/Omsk/2012 | E-11        | KU133586      | 39  | 439-CSF/RUS/Omsk/2013 | CV-B5       | KU133646      |
| 40  | 318-CSF/RUS/Omsk/2012 | E-11        | KU133601      | 40  |                 |             |               |
| 41  | 284-CSF/RUS/Omsk/2012 | E-18        | KU133587      | 41  |                 |             |               |
| 42  | 330-CSF/RUS/Omsk/2012 | E-18        | KU133609      | 42  |                 |             |               |
| 43  | 253-CSF/RUS/Omsk/2012 | E-32        | KU133569      | 43  |                 |             |               |
| 44  | 286-CSF/RUS/Omsk/2012 | E-30        | KU133588      | 44  |                 |             |               |
| 45  | 304-CSF/RUS/Omsk/2012 | E-14        | KU133595      | 45  |                 |             |               |
| 46  | 310-CSF/RUS/Omsk/2012 | CV-B2       | KU133598      | 46  |                 |             |               |
| 47  | 333-CSF/RUS/Omsk/2012 | E-15        | KU133611      | 47  |                 |             |               |

3.4. Retrospective Direct Genotyping of Enteroviruses Detected in CSFs of Patients Hospitalized in 2013

Seventy-one patients with suspected meningitis were admitted to the hospitals in Omskaya oblast in 2013. Enteroviruses were detected in 39 (54.9%) CSF specimens. Successful genotyping was achieved for all 39 positive samples. Eight serotypes of species B and 5 EV-A71 (Table 2) were identified in CSFs in 2013 and the phylogenetic analysis displayed that EV A71 from Omskaya oblast was related to EV A71 from China identified in 2008.

To avoid omission of the serotypes of species A (except EV-A71), species C, and species D, we used the method described by Nix et al. [23] or primers AN89 and AN88 for the second round of PCR, but none of these serotypes was detected.

The spectrum of EVs in 2012 changed in 2013 (Table 3) and these data conform to previous investigations [28]. The serotype E-6 was prevailing in 2012 and E-11 became prevailing in 2013.

Table 3. Number of enterovirus serotypes identified in patients with meningitis through direct serotyping in CSFs.

| Identified Serotype | No. and % (in Parentheses) of EV Serotype to All EVs Identified during the Corresponding Year |
|---------------------|---------------------------------------------------------------------------------------------|
|                     | 2012                                                                                       | 2013                        |
| Coxackievirus A9    | 11 (23.4)                                                                                  | 4 (10.3)                    |
| Coxackievirus B1    | 5 (10.6)                                                                                   | 0                           |
| Coxackievirus B2    | 1 (2.1)                                                                                    | 3 (7.7)                     |
| Coxackievirus B4    | 0                                                                                        | 1 (2.6)                     |
| Coxackievirus B5    | 0                                                                                        | 1 (2.6)                     |
| Echovirus 6         | 16 (34.1)                                                                                  | 0                           |
| Echovirus 7         | 0                                                                                        | 3 (7.7)                     |
| Echovirus 9         | 5 (10.7)                                                                                   | 0                           |
| Echovirus 11        | 3 (6.4)                                                                                    | 17 (43.5)                   |
| Echovirus 14        | 1 (2.1)                                                                                    | 0                           |
| Echovirus 15        | 1 (2.1)                                                                                    | 0                           |
| Echovirus 18        | 2 (4.3)                                                                                    | 2 (5.1)                     |
| Echovirus 30        | 1 (2.1)                                                                                    | 3 (7.7)                     |
| Echovirus 32        | 1 (2.1)                                                                                    | 0                           |
| Enterovirus A71     | 0                                                                                        | 5 (12.8)                    |
4. Discussion

According to the currently existing epidemiological data, the importance of non-polio enteroviruses (NPEVs) as the etiological agents of severe pathologies of CNS, heart, and pancreas rise considerably. It may be linked to the results of the Global Polio Eradication Initiative of World Health Organization (WHO) a great decrease of the Poliomyelitis morbidity and circulation of polio viruses, a replacement of the oral polio vaccine (OPV) by inactivated polio vaccine in many countries [29,30]. To date, viruses of serotypes belonging to species B and EV71 are some of the major etiological agents of severe neurological diseases and cardiomyopathies in developed countries [19,31,32]. For instance, EV-A71 and some coxsackieviruses are able to cause poliomyelitis-like acute flaccid paralysis [30,33]. Based on the importance of these viruses, we focused our investigation on them.

Several molecular serotyping methods for amplification of the whole EV VP1 genomic region or its part directly from clinical material were developed [22–24,31,34–38]. Evaluation of published highly sensitive methods developed for direct enterovirus serotyping showed that the seminested PCR described in [23] had the highest effectiveness for serotyping. The non-specific amplification observed with the method described in [24] may be due to the usage of degenerate primers in the second round of PCR.

The method described in this paper allowed us to identify the majority of EVs in the CSF samples. This technology also allowed amplifying the whole VP1 genomic region of the identified EVs, what is preferable for genotyping and phylogenetic purposes. We used species-specific primers for species B and serotype specific for EV-A71, and this perhaps ensued achievement of maximal sensitivity among tested methods. At the same time, it caused some disadvantages as it requires the usage of other primers in the second round of PCR in order to amplify the remainder of EV serotypes. This problem can be resolved by amplification of the VP1 gene in the second round of PCR with primers specific to EV species A, C, D. For detection of possibly missed EVs of these species, the method by Nix W.A. et al. [23] can be used. In our investigation, we have not revealed EVs which do not belong to species B or serotype EV71 with methods based on generic primers for the second round of PCR.

The ability to establish persistent infection is an intrinsic trait of EVs. One of the mechanisms for this phenomenon is the acquiring of deletions in the 5' region of EV RNA [39]. The persisting virus can be associated with adverse effects for the host. For example, enteroviral persistence in myocardium has been associated with progressive cardiac dysfunction. On the contrary, patients who eliminated the virus showed substantial improvement of hemodynamic parameters [40]. The experiments in mice suggest that enterovirus coxsackievirus B3 (CV-B3) may persist in the CNS as a low-level, non-cytolytic infection, causing ongoing inflammatory lesions [41]. Taking into consideration that the enterovirus genome can lose the particular sequences of the 5' non-coding genomic region during persistent infection, and this region has been widely used as a gold standard for EV detection [22,23], it appears that the amplification of VP1 sequence sequence could be more applicable for precise diagnostics of EV diseases. Besides, it provides more important information that can also furnish clues to virus transmission pathways during epidemiologic field investigations [23].

Considering the increasing role of NPEVs in the structure of infectious pathology, the development of anti-enteroviral vaccines and hyperimmune serums could be recommended. The vaccines against the most virulent serotypes and their genotypes can be developed and used based on epidemiological surveillance as, for instance, it is done for the prophylaxis of the influenza virus. The rapid accurate diagnosis could provide the timely correction of treatment using antiviral and specific drugs, thereby improving the course of the disease and prognosis. Highly sensitive and specific methods are required for precise diagnostics of enterovirus infections of CNS and heart. The method for direct serotyping of EVs described here allows quick determination of EV serotypes and provides information about the whole VP1 genomic region, and, therefore, could be useful in clinical, epidemiological surveillance and research practice.
5. Conclusions

Highly sensitive method for amplification of the genome region coding the whole enterovirus structural protein VP1 was developed. It demonstrated to be effective for investigation of the cerebrospinal fluids (CSF)—the clinical material with quite low viral loads. This method can be useful in scientific, clinical and epidemiological research.

Author Contributions: Alexandr Krasota participated in design of the experiment, performed experiments, analyzed the data, discussed the data and presented it at scientific seminars, and wrote the paper; Natalia Loginovskih provided the materials and contributed to experiment; Olga Ivanova contributed to reagents; Galina Lipskaya conceived the experiment, participated in design and discussion of the results and participated in editing of the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Knowles, N.; Hovi, T.; Hyypiä, T.; King, A.; Lindberg, A.; Pallansch, M.; Palmenberg, A.; Simmonds, P.; Skern, T.; Stanway, G.; et al. Family picornaviridae. In Virus Taxonomy. Ninth Report of the International Committee on Taxonomy of Viruses, 1st ed.; King, A., Adams, M., Carstens, E., Lefkowitz, E., Eds.; Elsevier Press: San Diego, CA, USA, 2012; Volume 1, pp. 855–880.
2. Chevaliez, S.; Szendroi, A.; Caro, V.; Balanant, J.; Guillot, S.; Berencsi, G.; Delpeyrroux, F. Molecular comparison of echovirus 11 strains circulating in Europe during an epidemic of multisystem hemorrhagic disease of infants indicates that evolution generally occurs by recombination. *Virology* 2004, 325, 56–70. [CrossRef] [PubMed]
3. Lindberg, A.M.; Anderson, P.; Savolainen, M.N.; Mulders, M.N.; Hovi, T. Evolution of the genome of human enterovirus B: Incongruence between phylogenies of the VP1 and 3CD regions indicates frequent recombination within the species. *J. Gen. Virol.* 2003, 84, 1223–1235. [CrossRef] [PubMed]
4. Mirand, A.; Henquell, C.; Archimbaud, C.; Peigue-Lafeuille, H.; Bailly, J. Emergence of echovirus 30 lineages is marked by serial genetic recombination events. *J. Gen. Virol.* 2004, 87, 166–176. [CrossRef] [PubMed]
5. Oberste, M.S.; Maher, K.; Pallansch, M.A. Evidence for frequent recombination within species human enterovirus B based on complete genomic sequences of all thirty-seven serotypes. *J. Virol.* 2004, 78, 855–867. [CrossRef] [PubMed]
6. Oprisan, G.; Combiescu, M.; Guillot, S.; Caro, V.; Combiescu, A.; Delpeyrroux, F.; Grainic, R. Natural genetic recombination between co-circulating heterotypic enteroviruses. *J. Gen. Virol.* 2002, 83, 2193–2200. [CrossRef] [PubMed]
7. Santti, J.; Hyypiä, T.; Kinnunen, L.; Salminen, M. Evidence of recombination among enteroviruses. *J. Virol.* 1999, 73, 8741–8749. [PubMed]
8. Simmonds, P.; Welch, J. Frequency and dynamics of recombination within different species of human enteroviruses. *J. Virol.* 2006, 80, 483–493. [CrossRef] [PubMed]
9. Harris, K.G.; Coyne, C.B. Enter at your own risk: How enteroviruses navigate the dangerous world of pattern recognition receptor signaling. *Cytokine* 2013, 63, 230–236. [CrossRef] [PubMed]
10. Lee, B.E.; Davies, H.D. Aseptic meningitis. *Curr. Opin. Infect. Dis.* 2007, 20, 272–277. [CrossRef] [PubMed]
11. Kelly, T.A.; O’Lorcain, P.; Moran, J.; Garvey, P.; McKeown, P.; Connell, J.; Cotter, S. Underreporting of viral encephalitis and viral meningitis, Ireland, 2005–2008. *Emerg. Infect. Dis.* 2013, 19, 1428–1436. [CrossRef] [PubMed]
12. Nathanson, N.; Kew, O.M. From emergence to eradication: The epidemiology of poliomyelitis deconstructed. *Am. J. Epidemiol.* 2010, 172, 1213–1229. [CrossRef] [PubMed]
13. Andréoletti, L.; Lévêque, N.; Boulagnon, C.; Brasselet, C.; Fornes, P. Viral causes of human myocarditis. *Arch. Cardiovasc. Dis.* 2009, 102, 559–568. [CrossRef] [PubMed]
14. Kühl, U.; Schulthess, H.P. Viral myocarditis. *Swiss. Med. Wkly.* 2014, 144, 1–9. [CrossRef] [PubMed]
15. Hober, D.; Sauter, P. Pathogenesis of type 1 diabetes mellitus: Interplay between enterovirus and host. *Nat. Rev. Endocrinol.* 2010, 6, 279–289. [CrossRef] [PubMed]
16. Rantakallio, P.; Jones, P.; Moring, J.; von Wendt, L. Association between central nervous system infections during childhood and adult onset schizophrenia and other psychoses: A 28-year follow-up. *Int. J. Epidemiol.* 1997, 26, 837–843. [CrossRef] [PubMed]
17. Fu, Y.C.; Chi, C.S.; Chiu, Y.T.; Hsu, S.L.; Hwang, B.; Jan, S.L.; Chan, P.Y.; Huang, F.L.; Chang, Y. Cardiac complications of enterovirus rhombencephalitis. *Arch. Dis. Child.* 2004, 89, 368–373. [CrossRef] [PubMed]

18. Kung, C.M.; King, C.C.; Lee, C.N.; Huang, L.M.; Lee, P.I.; Kao, C.L. Differences in replication capacity between enterovirus 71 isolates obtained from patients with encephalitis and those obtained from patients with herpangina in Taiwan. *J. Med. Virol.* 2007, 79, 60–68. [CrossRef] [PubMed]

19. Solomon, T.; Lewthwaite, P.; Perera, D.; Cardosa, M.J.; McMinn, P.; Ooi, M.H. Virology, epidemiology, pathogenesis, and control of enterovirus 71. *Lancet. Infect. Dis.* 2010, 10, 778–790. [CrossRef]

20. Tijmsa, A.; Franco, D.; Tucker, S.; Hilgenfeld, R.; Froyen, M.; Leyssen, P.; Neyts, J. The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication. *Antimicrob. Agents Chemother.* 2014, 58, 6990–6992. [CrossRef] [PubMed]

21. Volle, R.; Bailly, J.-L.; Mirand, A.; Pepeira, B.; Marque-Juillet, S.; Chambon, M.; Regagnon, C.; Brebion, A.; Henquell, C.; Peigue-Lafeuille, H.; et al. Variations in cerebrospinal fluid viral loads among enterovirus genotypes in patients hospitalized with laboratory-confirmed meningitis due to enterovirus. *J. Infect. Dis.* 2014, 210, 576–584. [CrossRef] [PubMed]

22. Mirand, A.; Henquell, C.; Archimbaud, C.; Chambon, M.; Charbonne, F.; Peigue-Lafeuille, H.; Bailly, J.-L. Prospective identification of enteroviruses involved in meningitis in 2006 through direct genotyping in cerebrospinal fluid. *J. Clin. Microbiol.* 2008, 46, 87–96. [CrossRef] [PubMed]

23. Nix, W.A.; Oberste, M.S.; Pallansch, M.A. Sensitive, seminested PCR amplification of VP1 sequences for direct identification of all interovirus serotypes from original clinical specimens. *J. Clin. Microbiol.* 2006, 44, 2698–2704. [CrossRef] [PubMed]

24. Casas, I.; Palacios, G.F.; Trallero, G.; Cisterna, D.; Freire, M.C.; Tennorio, A. Molecular characterization of human enteroviruses in clinical samples: Comparison between VP2, VP1, and RNA polymerase region using RT nested PCR assays and direct sequencing of products. *J. Med. Virol.* 2001, 65, 138–148. [CrossRef] [PubMed]

25. Oberste, M.S.; Penaranda, S.; Maher, K.; Pallansch, M.A. Complete genome sequences of all members of the species Human enterovirus A. *J. Gen. Virol.* 2004, 85, 1957–1607. [CrossRef] [PubMed]

26. Basic Local Alignment Search Tool. Available online: http://blast.ncbi.nlm.nih.gov/Blast.cgi (accessed on 11 August 2015).

27. Rose, T.M. CODEHOP-mediated PCR—A powerful technique for the identification and characterization of viral genomes. *Virol. J.* 2005, 15, 2–20.

28. Khettsuriani, N.; LaMonte-Fowlkes, A.; Oberste, M.S.; Pallansch, M.A. Enterovirus surveillance-United States, 1970–2005. *Morb. Mortal. Wkly. Rep.* 2006, 55, 1–20.

29. Bharti, O.K. Can non-polio enteroviruses be tamed with a vaccine to minimize paralysis caused by them? *World J. Vacc.* 2015, 5, 54–59. [CrossRef]

30. Dhole, T.N.; Ayyagari, A.; Chowdhary, R.; Shakya, A.K.; Shrivastav, N.; Datta, T.; Prakash, V. Non-polio enteroviruses in acute flaccid paralysis children of India: Vital assessment before polio eradication. *J. Clin. Virol.* 2008, 40, 1018–1024. [CrossRef] [PubMed]

31. Cabrero, M.; Echevarria, J.E.; González, I.; de Miguel, T.; Trallero, G. Molecular epidemiological study of HEV-B enteroviruses involved in the increase in meningitis cases occurred in Spain during 2006. *J. Med. Virol.* 2008, 80, 1018–1024. [CrossRef] [PubMed]

32. Yan, J.J.; Wang, J.R.; Liu, C.C.; Yang, H.B.; Su, I.J. An outbreak of enterovirus 71 infection in Taiwan 1998: A comprehensive pathological, virological, and molecular study on a case of fulminant encephalitis. *J. Clin. Virol.* 2000, 17, 13–22. [CrossRef]

33. Ooi, M.H.; Wong, S.C.; Lewthwaite, P.; Cardosa, M.J.; Solomon, T. Clinical features, diagnosis, and management of enterovirus 71. *Lancet Neurol.* 2010, 9, 1097–1105. [CrossRef]

34. Oberste, M.S.; Maher, K.; Kilpatrick, D.R.; Flemister, M.R.; Brown, B.A.; Pallansch, M.A. Typing of human enteroviruses by partial sequencing of VP1. *J. Clin. Microbiol.* 1999, 37, 1288–1293. [PubMed]

35. Caro, V.; Guillot, S.; Delpeyroux, F.; Crainic, R. Molecular strategy for “serotyping” of human enteroviruses. *J. Gen. Virol.* 2001, 82, 79–91. [CrossRef] [PubMed]

36. Itturiza-Gomara, M.; Megson, B.; Gray, J. Molecular detection and characterization of human enteroviruses directly from clinical samples using RT-PCR and DNA sequencing. *J. Med. Virol.* 2006, 75, 243–253. [CrossRef] [PubMed]
37. Leitch, E.C.; Harvala, H.; Robertson, I.; Ubillos, I.; Templeton, K.; Simmonds, P. Direct identification of human enterovirus serotypes in cerebrospinal fluid by amplification and sequencing of the VP1 region. *J. Clin. Virol.* 2009, 44, 119–124. [CrossRef] [PubMed]

38. Papadakis, G.; Chibo, D.; Druce, J.; Catton, M.; Birch, C. Detection and genotyping of enteroviruses in cerebrospinal fluid in patients in Victoria, Australia, 2007–2013. *J. Med. Virol.* 2014, 86, 1609–1613. [CrossRef] [PubMed]

39. Chapman, N.M.; Kim, K.S.; Drescher, K.M.; Oka, K.; Tracy, S. 5′ terminal deletions in the genome of the coxsackievirus B2 strain occurred naturally in human heart. *Virology* 2008, 375, 480–491. [CrossRef] [PubMed]

40. Kühl, U.; Pauschinger, M.; Seeberg, B.; Lassner, D.; Noutsias, M.; Poller, W.; Schultheiss, H.P. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. *Circulation* 2005, 112, 1965–1970. [CrossRef] [PubMed]

41. Feuer, R.; Ruller, C.M.; An, N.; Tabor-Godwin, J.M.; Rhoades, R.E.; Maciejewski, S.; Pagarigan, R.R.; Cornell, C.T.; Crocker, S.; Kiosses, W.; et al. Viral persistence and chronic immunopathology in the adult central nervous system following Coxsackievirus infection during the neonatal period. *J. Virol.* 2009, 83, 9356–9369. [CrossRef] [PubMed]

© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).